Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.75% |
| 2 | Technology | 13.74% |
| 3 | Healthcare | 12.69% |
| 4 | Industrials | 11.51% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
MasTec
MTZ
$23.5B
| $1.03M | ﹤0.01% |
+27,000
| New | +$916K |
|
|
IEC
2527
DELISTED
IEC Electronics Corp.
IEC
| $1.03M | ﹤0.01% |
289,300
+32,000
| +12% | +$120K |
|
|
HOLI
2528
DELISTED
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
| $1.03M | ﹤0.01% |
56,205
+21,187
| +61% | +$420K |
|
2529
Scully Royalty
SRL
$91.4M
| $1.02M | ﹤0.01% |
105,143
+13,100
| +14% | +$134K |
|
|
FCCY
2530
DELISTED
1st Constitution Bancorp
FCCY
| $1.02M | ﹤0.01% |
+54,600
| New | +$818K |
|
|
AXAS
2531
DELISTED
Abraxas Petroleum Corp
AXAS
| $1.02M | ﹤0.01% |
+19,856
| New | +$782K |
|
2532
Flexsteel Industries
FLXS
$303M
| $1.02M | ﹤0.01% |
16,500
-9,685
| -37% | -$503K |
|
|
APTS
2533
DELISTED
Preferred Apartment Communities, Inc.
APTS
| $1.01M | ﹤0.01% |
68,000
-11,400
| -14% | -$152K |
|
2534
Upland Software
UPLD
$17.3M
| $1.01M | ﹤0.01% |
11,300
+680
| +6% | +$59.9K |
|
2535
Alphatec Holdings
ATEC
$1.51B
| $1.01M | ﹤0.01% |
313,545
+144,300
| +85% | +$782K |
|
2536
CytomX Therapeutics
CTMX
$723M
| $1M | ﹤0.01% |
+91,200
| New | +$1.1M |
|
|
CRHM
2537
DELISTED
CRH Medical Corporation
CRHM
| $1M | ﹤0.01% |
190,600
-41,300
| -18% | -$209K |
|
|
PPIH
2538
Perma-Pipe International
PPIH
$221M
| $1M | ﹤0.01% |
123,500
+13,800
| +13% | +$111K |
|
|
ENG
2539
DELISTED
ENGlobal Corp
ENG
| $998K | ﹤0.01% |
52,204
+9,625
| +23% | +$118K |
|
|
KW
2540
DELISTED
Kennedy-Wilson Holdings
KW
| $995K | ﹤0.01% |
48,520
-78,480
| -62% | -$1.68M |
|
|
EHIC
2541
DELISTED
eHi Car Services Limited
EHIC
| $987K | ﹤0.01% |
108,900
+82,400
| +311% | +$830K |
|
|
LOAN
2542
Manhattan Bridge Capital
LOAN
$47.3M
| $984K | ﹤0.01% |
129,500
+25,400
| +24% | +$172K |
|
|
SGMO
2543
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $982K | ﹤0.01% |
321,819
-272,681
| -46% | -$993K |
|
|
GST
2544
DELISTED
Gastar Exploration Inc.
GST
| $980K | ﹤0.01% |
632,554
+532,580
| +533% | +$643K |
|
|
SHLM
2545
DELISTED
Schulman (A.) Inc
SHLM
| $975K | ﹤0.01% |
+29,141
| New | +$924K |
|
2546
Sinclair Inc
SBGI
$1.06B
| $973K | ﹤0.01% |
29,171
-490,921
| -94% | -$14.6M |
|
2547
Virco
VIRC
$95.3M
| $973K | ﹤0.01% |
226,300
-5,700
| -2% | -$24K |
|
2548
TIM SA
TIMB
$8.28B
| $968K | ﹤0.01% |
82,000
-111,238
| -58% | -$1.39M |
|
|
HSTO
2549
DELISTED
Histogen Inc. Common Stock
HSTO
| $968K | ﹤0.01% |
919
+606
| +194% | +$275K |
|
2550
Aspen Aerogels
ASPN
$498M
| $964K | ﹤0.01% |
233,300
-100
| -0% | -$487 |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.